Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  The Lancet

• Publication date

  2010-05-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(10)60482-5PMID 20472173PMCID PMC2904571
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modeling Survival Data

  2011cited by this paper
• Screening panels for detection of monoclonal gammopathies.

  2009cited by this paper
• Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.

  2009cited by this paper
• Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study.

  2009cited by this paper
• A monoclonal gammopathy precedes multiple myeloma in most patients.

  2009cited by this paper
• Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

  2009cited by this paper
• Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease.

  2008cited by this paper
• Demonstration of changes in plasma cell subsets in multiple myeloma.

  2007cited by this paper
• Prevalence of monoclonal gammopathy of undetermined significance.

  2006cited by this paper
• Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays.

  2006cited by this paper
• Prevalence of Light-Chain Monoclonal Gammopathy of Undetermined Significance (LC-MGUS) among Olmsted County, Minnesota Residents Aged 50 Years or Greater.

  2006cited by this paper
• International staging system for multiple myeloma.

  2005cited by this paper
• Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.

  2005cited by this paper
• Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.

  2005cited by this paper
• Incidence of multiple myeloma in Olmsted County, Minnesota

  2004cited by this paper
• Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level.

  2004cited by this paper
• Detection of Bence Jones myeloma and monitoring of myeloma chemotherapy using immunoassays specific for free immunoglobulin light chains.

  2003cited by this paper
• Review of 1027 patients with newly diagnosed multiple myeloma.

  2003cited by this paper
• Serum test for assessment of patients with Bence Jones myeloma.

  2003cited by this paper
• Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

  2003cited by this paper
• A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

  2002cited by this paper
• Serum Reference Intervals and Diagnostic Ranges for Free κ and Free λ Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light Chains

  2002cited by this paper
• Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.

  2002cited by this paper
• Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma.

  2001cited by this paper
• Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.

  2001cited by this paper
• Modeling Survival Data: Extending the Cox Model

  2000cited by this paper
• Long-Term Trends in Hip Fracture Prevalence: The Influence of Hip Fracture Incidence and Survival

  1998cited by this paper
• Extending the Cox Model

  1997cited by this paper
• "Idiopathic" Bence Jones proteinuria: long-term follow-up in seven patients.

  1982cited by this paper
• Monoclonal gammopathy of undetermined significance. Natural history in 241 cases.

  1978cited by this paper

• Next-Generation Biomarkers in Multiple Myeloma: Advancing Diagnosis, Risk Stratification, and Precision Therapy Beyond Current Guidelines.

  2026cites this paper
• An odyssey of monoclonal gammopathies: focusing on precursors and the progression from MGUS and SMM to multiple Myeloma, with a brief overview of novel therapeutic strategies

  2026cites this paper
• Glomerulonefrite C3 associada à gamopatia monoclonal de significância renal: um desafio diagnóstico e terapêutico

  2025cites this paper
• Capillary Electrophoresis Not Detecting Elevated Concentrations of Monoclonal Free Light Chains

  2025cites this paper
• Developing antisense therapeutics for multiple myeloma

  2025cites this paper
• Assessment of serum free light chain measurements in a large Chinese chronic kidney disease cohort: a multicenter real-world study

  2025cites this paper
• Precursor plasma cell disorders: Classification, risk stratification, and emerging role of early interception.

  2025cites this paper
• Predicting the Progression from Asymptomatic to Symptomatic Multiple Myeloma and Stage Classification Using Gene Expression Data

  2025cites this paper
• Lecture 4. Clonal Plasma Cell Precursors

  2025cites this paper
• C3 glomerulonephritis associated with monoclonal gammopathy of renal significance: a diagnostic and therapeutic challenge

  2025cites this paper
• Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance: A Review.

  2025cites this paper
• Monoclonal gammopathies and their management in Gaucher disease type 1

  2025cites this paper
• Monoclonal Gammopathy of Undetermined Significance.

  2025cites this paper
• New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance

  2025cites this paper
• Monoclonal Gammopathy in Amyotrophic Lateral Sclerosis: No Impact on Clinical Progression and Immunotherapy Outcomes

  2025cites this paper
• A rare case of light chain monoclonal gammopathy of undetermined significance with pulmonary involvement and its regression with CyBorD therapy: A case report

  2025cites this paper
• Challenges, Difficulties, and Delayed Diagnosis of Multiple Myeloma

  2025cites this paper
• Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection.

  2024cites this paper
• The role of nutrition and gut microbiome in the progression of multiple myeloma and its precursor disease

  2024cites this paper
• From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy

  2024cites this paper
• From MGUS to multiple myeloma: Unraveling the unknown of precursor states.

  2024cites this paper
• Monoclonal gammopathy of undetermined significance with multiple paraproteins: A population‐based screening study

  2024cites this paper
• Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance

  2024cites this paper
• C3 glomerulonephritis associated with monoclonal gammopathy of renal significance: a diagnostic and therapeutic challenge

  2024cites this paper
• Performance Characteristics and Limitations of the Available Assays for the Detection and Quantitation of Monoclonal Free Light Chains and New Emerging Methodologies

  2024cites this paper
• Association Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined Significance

  2024cites this paper
• Stromal alterations in patients with monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma

  2024cites this paper
• The effects of short-term, progressive exercise training on disease activity in smouldering multiple myeloma and monoclonal gammopathy of undetermined significance: a single-arm pilot study

  2024cites this paper
• Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM study.

  2024cites this paper
• Kidney thrombotic microangiopathy with concurrent monoclonal gammopathy.

  2024cites this paper
• Diagnostic and Therapeutic Aspects of Monoclonal Gammopathies of Renal Significance (MGRS): An Update

  2024influential citation
• Clinical significance of FLC tests in patients without other evidence of hematologic disorder

  2024cites this paper
• Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions

  2024cites this paper
• SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma.

  2024cites this paper
• MGCS: where do we stand today?

  2024cites this paper
• Screening in Multiple Myeloma and Its Precursors: Are We There Yet?

  2024cites this paper
• Laboratory practice is central to earlier myeloma diagnosis: Utilizing a primary care diagnostic tool and laboratory guidelines integrated into haematology services

  2024cites this paper
• Monoclonal gammopathy of undetermined significance and the risk of thrombotic events: Results from iStopMM, a prospective population‐based screening study

  2024cites this paper
• Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and Sweden

  2024cites this paper
• The significance of free light-chain ratio in light-chain monoclonal gammopathy of undetermined significance: a flow cytometry sub-study of the iStopMM screening study

  2024cites this paper
• Serum free light chains in a racially diverse population including African Americans and populations from South Africa.

  2024cites this paper
• Adopting the new iStopMM-based criteria for light-chain monoclonal gammopathy of undetermined significance: an ongoing debate

  2024cites this paper
• LILRB4 regulates multiple myeloma development through STAT3-PFKFB1 pathway

  2024cites this paper
• Prevalence of monoclonal gammopathy of undetermined significance in Eswatini: a population-based study in Africa

  2024cites this paper
• Rapidly Progressive Glomerulonephritis Secondary to Immunoglobulin M-associated Monoclonal Gammopathy of Renal Significance: A Report of a Rare Case

  2024cites this paper
• Kappa Free Light Chain Drift Prompts the Need for a New Upper Limit of Normal Free Light Chain Ratio to Avoid an Epidemic of Kappa Light Chain Monoclonal Gammopathy of Undermined Significance.

  2023cites this paper
• A case of systemic amyloidosis showing papular/nodular lesions due to Waldenström's macroglobulinemia

  2023cites this paper
• Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study

  2023cites this paper
• MyeloDB: a multi-omics resource for multiple myeloma

  2023influential citation
• Investigation and management of the monoclonal gammopathy of undetermined significance

  2023cites this paper
• Use of the Current Standard of Practice Serum Free Light Chains (sFLC) Reference Interval Puts Black Patients at 5 Times Higher Odds for Light Chain Monoclonal Gammopathy of Undetermined Significance (LC-MGUS).

  2023cites this paper
• An overview of multiple myeloma: A monoclonal plasma cell malignancy’s diagnosis, management, and treatment modalities

  2023influential citation
• Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.

  2023cites this paper
• miRNAs and Multiple Myeloma: Focus on the Pathogenesis, Prognosis, and Drug Resistance

  2023cites this paper
• Use of Clinical Decision Support to Improve the Laboratory Evaluation of Monoclonal Gammopathies.

  2023cites this paper
• Screening for and diagnosis of monoclonal gammopathy

  2023cites this paper
• A Comprehensive Multidisciplinary Diagnostic Algorithm for the Early and Efficient Detection of Amyloidosis.

  2022cites this paper
• Monoclonal Gammopathy of Undetermined Significance in Patients With Transthyretin Amyloidosis (ATTR): Analysis Using the iStopMM Criteria.

  2022cites this paper
• Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal

  2022cites this paper
• Noninvasive Diagnostics of Renal Amyloidosis: Current State and Perspectives

  2022cites this paper
• Monoclonal gammopathy of undetermined significance: evaluation, risk assessment, management, and beyond

  2022cites this paper
• Monoklonální gamapatie nejistého významu a monoklonální gamapatie klinického významu

  2022cites this paper
• [Cardiac amyloidosis: State of art in 2022].

  2022cites this paper
• Multiple Myeloma With a Rare Presentation at Preserved Uninvolved Immunoglobulins

  2022cites this paper
• Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives

  2022cites this paper
• Prevalence of monoclonal gammopathy of undetermined significance in Black South African men.

  2022cites this paper
• Myeloma precursor disease (MGUS) among rescue and recovery workers exposed to the World Trade Center disaster

  2022influential citation
• The potential role of mass spectrometry for the identification and monitoring of patients with plasma cell disorders: Where are we now and which questions remain unanswered?

  2022cites this paper
• Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

  2022cites this paper
• Smoldering multiple myeloma current treatment algorithms

  2022cites this paper
• Autoimmunity, Infections, and the Risk of Monoclonal Gammopathy of Undetermined Significance

  2022cites this paper
• The Path Forward in Multiple Myeloma: 2021 Jan Waldenstrom Award Lecture.

  2022cites this paper
• A genetic risk score of alleles related to MGUS interacts with socioeconomic position in a population-based cohort

  2022cites this paper
• Combined serum free light chain predicts prognosis in acute kidney injury following cardiovascular surgery

  2022cites this paper
• Our cases of monoclonal gammopathy renal significance (MGRS): Single center experience

  2022cites this paper
• Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.

  2022cites this paper
• iStopMM: A Monumental Effort

  2022cites this paper
• Light Chain Restriction in Proximal Tubules—Implications for Light Chain Proximal Tubulopathy

  2022cites this paper
• Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study

  2022influential citation
• Genome Instability in Multiple Myeloma: Facts and Factors

  2021cites this paper
• Primary oral mucosa-associated lymphoid tissue (MALT) lymphoma in patient with monoclonale gammopathy: a rare case report

  2021cites this paper
• Vitamin D Deficiency, Osteoporosis and Effect on Autoimmune Diseases and Hematopoiesis: A Review

  2021cites this paper
• Involvement of Alarmins in the Pathogenesis and Progression of Multiple Myeloma

  2021cites this paper
• The Role of New Imaging Technologies in the Diagnosis of Cardiac Amyloidosis.

  2021cites this paper
• Cardiovascular Involvement in Transthyretin Cardiac Amyloidosis.

  2021cites this paper
• Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study

  2021cites this paper
• Diagnosis of wild‐type transthyretin amyloid cardiomyopathy in Japan: red‐flag symptom clusters and diagnostic algorithm

  2021cites this paper
• Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies: Guideline From the College of American Pathologists in Collaboration With the American Association for Clinical Chemistry and the American Society for Clinical Pathology.

  2021cites this paper
• Protein electrophoresis and immunofixation

  2021cites this paper
• Amyloid Heart Disease

  2021cites this paper
• MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients

  2021cites this paper
• Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population‐based cohort study

  2021cites this paper
• Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance.

  2021cites this paper
• Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies

  2021cites this paper
• Autoimmune Coagulation Factor X Deficiency as a Rare Acquired Hemorrhagic Disorder: A Literature Review

  2021cites this paper
• Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 Cases.

  2021cites this paper
• Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events.

  2021cites this paper
• Monoclonal gammopathy in autoimmune diseases: Analysis and follow-up of 160 cases in a tertiary center in China.

  2021cites this paper
• A Comparison of gel (Hydragel 30) and capillary (Capillarys III Tera) electrophoresis for the characterization of human serum proteins

  2021cites this paper
• Monoclonal Gammopathies of Renal Significance: Renal Biopsy and Beyond

  2020cites this paper